WOYZEK® Nicotine Inhaler Is Going To Sink Big Ships

June 2, 2010 - PRLog -- The WOYZEK® inhaler is a clean pharmaceutical product developed entirely in Austria. WOYZEK®’s pharmacokinetic action – absorption of nicotine in pulmonary alveoli and transport to the brain - is impressive. The sensory and pharmacokinetic effects are so close to the cigarette that some blindfolded smokers may be unable to distinguish their usual cigarette brands.

Drugs and therapies currently available for smoking cessation show rather disappointing efficacies. 80-90% of cigarette smokers who attempt to quit fail eventually when applying available drugs and therapies. The WOYZEK® inhaler is particularly addressing this group of smokers. Cigarette smokers are asking for rapid nicotine delivery. WOYZEK® is providing this together with all other sensory effects of cigarettes. The WOYZEK® inhaler will boost the abstinence rate far above the 50 percent mark.

Buchberger Laboratories Austria, the company that has developed the WOYZEK® inhaler, is looking for corporate partners and investors who want to join bringing the inhaler to market.

Dr. H.M. Buchberger, Founder of Buchberger Laboratories: “There has never been a product so close to the cigarette reassembling tobacco smoke and its effects so impressively as the WOYZEK® inhaler. We have developed the inhaler and we have patented the technology. Now let us sink big ships!”

Find more detailed info at  http://www.woyzek.com

Buchberger Laboratories Austria
mail: P.O. Box 5, A-4470 Enns, Austria

Contact Person:
Dr. Helmut Buchberger, Managing Director
Phone: +46 8 501 64 512

Contact Us:
Santa Clara:   +1 408 400-3801
London:   +44 20 8133-1205
Stockholm: +46 8 501 64 512
Sydney: +61 2 8006-5010
Hong Kong: +852 8198 2405

http://www.buchberger-pharma.com
http://www.woyzek.com

# # #

About Buchberger Laboratories Austria:
Buchberger Laboratories Austria engages in the research, development and commercialization of inhalers, especially nicotine inhalers, and corresponding drug formulations. The company’s lead product candidate WOYZEK® is ready to build commercial prototypes to be tested in clinical trials.